At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NVAX Novavax
Trading 12-23 12:58:51 EST
6.83
-0.06
-0.94%
High6.90Low6.74Vol1.47M
Open6.85D1 Closing6.89Amplitude2.32%
Mkt Cap1.11BTradable Cap933.14MTotal Shares162.50M
T/O10.02MT/O Rate1.08%Tradable Shares136.72M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Novavax Inc. Stock Rises 3.5%, Outperforms Peers
Dow Jones  ·  12-23 05:35
Novavax Inc. Stock Rises 3.5%, Outperforms Peers
Novavax (NVAX) Valuation Check as FDA Scrutiny Rises and Activist Pushes for Possible Sale
Simply Wall St.  ·  12-14
Novavax (NVAX) Valuation Check as FDA Scrutiny Rises and Activist Pushes for Possible Sale
Novavax Inc. Stock Underperforms Friday When Compared To Competitors
Dow Jones  ·  12-13
Novavax Inc. Stock Underperforms Friday When Compared To Competitors
FDA intends to put most serious warning on COVID vaccines, CNN reports
Reuters  ·  12-12
FDA intends to put most serious warning on COVID vaccines, CNN reports
BRIEF-FDA Probes If Covid Shots Might Be Linked To Deaths Of Adults- Bloomberg News
Reuters  ·  12-10
BRIEF-FDA Probes If Covid Shots Might Be Linked To Deaths Of Adults- Bloomberg News
FDA Probes IF Covid Shots Might Be Linked to Deaths of Adults- Bloomberg News
THOMSON REUTERS  ·  12-10
FDA Probes IF Covid Shots Might Be Linked to Deaths of Adults- Bloomberg News
Novavax Inc. Stock Underperforms Tuesday When Compared To Competitors
Dow Jones  ·  12-03
Novavax Inc. Stock Underperforms Tuesday When Compared To Competitors
Mabion SA Q3 revenue surges sevenfold to PLN 4.1 million
Reuters  ·  12-02
Mabion SA Q3 revenue surges sevenfold to PLN 4.1 million
Novavax Inc. Stock Slips 5.1%, Underperforms Peers
Dow Jones  ·  12-02
Novavax Inc. Stock Slips 5.1%, Underperforms Peers
Stock Track | Novavax Plummets 5.04% as FDA Links COVID Vaccines to Child Deaths, Tightens Approval Rules
Stock Track  ·  12-02
Stock Track | Novavax Plummets 5.04% as FDA Links COVID Vaccines to Child Deaths, Tightens Approval Rules
Stock Track | Novavax Plummets 5.04% Intraday as FDA Memo Links Child Deaths to COVID Vaccines
Stock Track  ·  12-02
Stock Track | Novavax Plummets 5.04% Intraday as FDA Memo Links Child Deaths to COVID Vaccines
BUZZ-U.S. STOCKS ON THE MOVE-Ideaya Biosciences, Omnicom Group, Targa Resources
Reuters  ·  12-02
BUZZ-U.S. STOCKS ON THE MOVE-Ideaya Biosciences, Omnicom Group, Targa Resources
Vaccine Stocks Falls as FDA Vows to Impose New Vaccine Requirements
Tiger Newspress  ·  12-01
Vaccine Stocks Falls as FDA Vows to Impose New Vaccine Requirements
BUZZ-U.S. STOCKS ON THE MOVE-Coupang, Zscaler, gold miners
Reuters  ·  12-01
BUZZ-U.S. STOCKS ON THE MOVE-Coupang, Zscaler, gold miners
Shares of Some U.S. Vaccine Makers Fall Premarket After FDA Memo Links Child Deaths to Covid Shots
THOMSON REUTERS  ·  12-01
Shares of Some U.S. Vaccine Makers Fall Premarket After FDA Memo Links Child Deaths to Covid Shots
Moderna Down 3.4%, Novavax Down 1.4%
THOMSON REUTERS  ·  12-01
Moderna Down 3.4%, Novavax Down 1.4%
BUZZ-Vaccine makers fall after US FDA memo links child deaths to COVID shots
Reuters  ·  12-01
BUZZ-Vaccine makers fall after US FDA memo links child deaths to COVID shots
Novavax Inc. Stock Outperforms Competitors On Strong Trading Day
Dow Jones  ·  11-29
Novavax Inc. Stock Outperforms Competitors On Strong Trading Day
Why Novavax (NVAX) Is Up 9.6% After Pivot to Partnerships and Higher 2025 Guidance
Simply Wall St.  ·  11-27
Why Novavax (NVAX) Is Up 9.6% After Pivot to Partnerships and Higher 2025 Guidance
Novavax Inc. Stock Climbs 3.9%, Outperforms Peers
Dow Jones  ·  11-27
Novavax Inc. Stock Climbs 3.9%, Outperforms Peers

Introduction

Company Name.
Novavax
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Issue price:
--